EA201591733A1 - Секвестранты предшественников конечного продукта усиленного гликозилирования (age) - Google Patents
Секвестранты предшественников конечного продукта усиленного гликозилирования (age)Info
- Publication number
- EA201591733A1 EA201591733A1 EA201591733A EA201591733A EA201591733A1 EA 201591733 A1 EA201591733 A1 EA 201591733A1 EA 201591733 A EA201591733 A EA 201591733A EA 201591733 A EA201591733 A EA 201591733A EA 201591733 A1 EA201591733 A1 EA 201591733A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- age
- secvestrants
- precondents
- end product
- sequestrants
- Prior art date
Links
- 239000007795 chemical reaction product Substances 0.000 title 1
- 230000013595 glycosylation Effects 0.000 title 1
- 238000006206 glycosylation reaction Methods 0.000 title 1
- 239000002243 precursor Substances 0.000 abstract 4
- 239000003352 sequestering agent Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 125000004989 dicarbonyl group Chemical group 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 abstract 1
- 230000000378 dietary effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Polymers & Plastics (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792719P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/024436 WO2014150873A1 (en) | 2013-03-15 | 2014-03-12 | Sequestrants of advanced glycation end product (age) precursors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201591733A1 true EA201591733A1 (ru) | 2016-01-29 |
Family
ID=50439508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201591733A EA201591733A1 (ru) | 2013-03-15 | 2014-03-12 | Секвестранты предшественников конечного продукта усиленного гликозилирования (age) |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20160024233A1 (enExample) |
| EP (1) | EP2968403A1 (enExample) |
| JP (4) | JP2016512830A (enExample) |
| KR (1) | KR20150130492A (enExample) |
| CN (1) | CN105188718A (enExample) |
| AR (1) | AR095593A1 (enExample) |
| AU (2) | AU2014235500A1 (enExample) |
| BR (1) | BR112015023404A8 (enExample) |
| CA (1) | CA2906501A1 (enExample) |
| CL (1) | CL2015002624A1 (enExample) |
| CR (1) | CR20150545A (enExample) |
| DO (1) | DOP2015000221A (enExample) |
| EA (1) | EA201591733A1 (enExample) |
| HK (1) | HK1220607A1 (enExample) |
| IL (1) | IL241406A0 (enExample) |
| MA (1) | MA38487A1 (enExample) |
| MX (1) | MX2015012843A (enExample) |
| PE (1) | PE20151766A1 (enExample) |
| PH (1) | PH12015502019A1 (enExample) |
| SG (2) | SG11201506413PA (enExample) |
| TN (1) | TN2015000390A1 (enExample) |
| TW (1) | TW201521744A (enExample) |
| UY (1) | UY35441A (enExample) |
| WO (1) | WO2014150873A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41202A (fr) * | 2014-12-18 | 2017-10-24 | Genzyme Corp | Copolymères polydiallymine réticulé pour le traitement du diabète de type 2 |
| BR112020003638A2 (pt) * | 2017-08-31 | 2020-09-01 | Cytosorbents Corporation | redução de produtos finais de glicação avançada a partir de fluidos corporais |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985938A (en) * | 1997-11-05 | 1999-11-16 | Geltex Pharmaceuticals, Inc. | Method for reducing oxalate |
| ES2637020T3 (es) * | 2001-04-18 | 2017-10-10 | Genzyme Corporation | Uso de polímero de amina para reducir la glucosa sérica |
| AU2003263010A1 (en) * | 2003-09-02 | 2005-04-21 | Genzyme Corporation | Method for reducing vascular inflammation |
| US7459502B2 (en) * | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| US7385012B2 (en) * | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
| JP2007523908A (ja) * | 2004-02-17 | 2007-08-23 | ダイナミス セラピューティクス インコーポレイテッド | フルクトサミン３キナーゼ並びにコラーゲン及びエラスチンの形成 |
| FR2883873B1 (fr) * | 2005-03-31 | 2009-07-10 | Pharmamens Sarl | Inhibiteurs d'age |
| US9181364B2 (en) * | 2010-02-24 | 2015-11-10 | Relypsa, Inc. | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants |
-
2014
- 2014-03-12 CA CA2906501A patent/CA2906501A1/en not_active Abandoned
- 2014-03-12 BR BR112015023404A patent/BR112015023404A8/pt not_active Application Discontinuation
- 2014-03-12 MX MX2015012843A patent/MX2015012843A/es unknown
- 2014-03-12 WO PCT/US2014/024436 patent/WO2014150873A1/en not_active Ceased
- 2014-03-12 JP JP2016501535A patent/JP2016512830A/ja active Pending
- 2014-03-12 AU AU2014235500A patent/AU2014235500A1/en not_active Abandoned
- 2014-03-12 SG SG11201506413PA patent/SG11201506413PA/en unknown
- 2014-03-12 US US14/776,059 patent/US20160024233A1/en not_active Abandoned
- 2014-03-12 SG SG10201707590XA patent/SG10201707590XA/en unknown
- 2014-03-12 KR KR1020157028860A patent/KR20150130492A/ko not_active Withdrawn
- 2014-03-12 CN CN201480026330.6A patent/CN105188718A/zh active Pending
- 2014-03-12 HK HK16108617.8A patent/HK1220607A1/zh unknown
- 2014-03-12 EP EP14715503.0A patent/EP2968403A1/en not_active Withdrawn
- 2014-03-12 PE PE2015001994A patent/PE20151766A1/es unknown
- 2014-03-12 EA EA201591733A patent/EA201591733A1/ru unknown
- 2014-03-12 MA MA38487A patent/MA38487A1/fr unknown
- 2014-03-13 TW TW103108910A patent/TW201521744A/zh unknown
- 2014-03-14 UY UY0001035441A patent/UY35441A/es not_active Application Discontinuation
- 2014-03-17 AR ARP140101218A patent/AR095593A1/es unknown
-
2015
- 2015-09-04 TN TN2015000390A patent/TN2015000390A1/en unknown
- 2015-09-08 DO DO2015000221A patent/DOP2015000221A/es unknown
- 2015-09-09 PH PH12015502019A patent/PH12015502019A1/en unknown
- 2015-09-09 IL IL241406A patent/IL241406A0/en unknown
- 2015-09-11 CL CL2015002624A patent/CL2015002624A1/es unknown
- 2015-10-13 CR CR20150545A patent/CR20150545A/es unknown
-
2017
- 2017-12-14 US US15/842,177 patent/US20180265613A1/en not_active Abandoned
-
2018
- 2018-04-25 JP JP2018083623A patent/JP2018135365A/ja active Pending
-
2019
- 2019-02-22 AU AU2019201259A patent/AU2019201259A1/en not_active Abandoned
- 2019-12-06 JP JP2019220818A patent/JP2020055850A/ja active Pending
-
2021
- 2021-12-17 JP JP2021204770A patent/JP2022037143A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CR20150545A (es) | 2015-12-01 |
| SG11201506413PA (en) | 2015-09-29 |
| EP2968403A1 (en) | 2016-01-20 |
| JP2018135365A (ja) | 2018-08-30 |
| PH12015502019A1 (en) | 2016-01-11 |
| BR112015023404A2 (pt) | 2017-07-18 |
| BR112015023404A8 (pt) | 2019-12-03 |
| CA2906501A1 (en) | 2014-09-25 |
| MX2015012843A (es) | 2016-08-08 |
| AU2014235500A1 (en) | 2015-11-05 |
| US20160024233A1 (en) | 2016-01-28 |
| HK1220607A1 (zh) | 2017-05-12 |
| KR20150130492A (ko) | 2015-11-23 |
| CN105188718A (zh) | 2015-12-23 |
| TN2015000390A1 (en) | 2017-01-03 |
| PE20151766A1 (es) | 2015-12-11 |
| SG10201707590XA (en) | 2017-11-29 |
| TW201521744A (zh) | 2015-06-16 |
| CL2015002624A1 (es) | 2016-03-11 |
| US20180265613A1 (en) | 2018-09-20 |
| MA38487A1 (fr) | 2017-12-29 |
| DOP2015000221A (es) | 2015-12-15 |
| JP2022037143A (ja) | 2022-03-08 |
| JP2020055850A (ja) | 2020-04-09 |
| AR095593A1 (es) | 2015-10-28 |
| JP2016512830A (ja) | 2016-05-09 |
| IL241406A0 (en) | 2015-11-30 |
| WO2014150873A1 (en) | 2014-09-25 |
| UY35441A (es) | 2014-10-31 |
| AU2019201259A1 (en) | 2019-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL264025A (en) | Novel fatty acid-modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease | |
| UA117072C2 (uk) | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини, і cd3, що не є людським | |
| EA201691940A1 (ru) | Новые соединения | |
| CL2013003406A1 (es) | Compuestos derivados de dolastatina unidos a aminoacidos no naturales; procedimiento de preparacion; composiciones farmaceuticas, útiles en el tratamiento del cancer de mamas. | |
| EA201591166A1 (ru) | Ингибиторы аутотаксина | |
| EA201501032A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
| PH12015502275B1 (en) | Therapuetic uses of empagliflozin | |
| MX343687B (es) | Compuestos sulfonamida tricíclica y métodos para su fabricación y uso. | |
| EA201391644A1 (ru) | Частично насыщенные трициклические соединения и способы их получения и применения | |
| MX340985B (es) | Compuestos de n-heteroarilo. | |
| MX349224B (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa. | |
| MX2013011124A (es) | Compuestos para el tratamiento del sindrome metabolico. | |
| EA201791432A1 (ru) | Композиции на основе пролекарства монометилфумарата | |
| PE20151746A1 (es) | Compuestos biciclicos | |
| MX2015013066A (es) | Usos terapéuticos para anticuerpos contra vegfr1. | |
| BR112015016033A2 (pt) | composições e métodos para tratamento de infecções por bactérias | |
| AU2017261919A1 (en) | Fat and medical uses thereof | |
| BR112015009816A2 (pt) | composições de moldagem e sobremoldagem para dispositivos eletrônicos | |
| CL2015001881A1 (es) | Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición. | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| EA201591733A1 (ru) | Секвестранты предшественников конечного продукта усиленного гликозилирования (age) | |
| EA201500737A1 (ru) | Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов | |
| FR2978012B1 (fr) | Agent pour le traitement des bois de vigne | |
| EA201401045A1 (ru) | Соединения для лечения заболеваний, связанных с ишемией-реперфузией | |
| EA201690938A1 (ru) | Соединения для лечения диабета и осложнений, возникающих из-за этого заболевания |